Merck & Co., Inc. (MRK)’s Weakest Blockbuster?
From Insider Monkey - Free Hedge Fund and Insider Trading Data
February 20, 2013 - 11:11pm
Merck & Co., Inc. (NYSE:MRK)‘s rheumatoid arthritis blockbuster Remicade provides a tricky entry in this series about the company’s main products, now that Singulair is off-patent. Remicade had net sales of $2.1 billion last year, which seems minuscule compared with the more than $9 billion AbbVie Inc (NYSE:ABBV) scored with Humira. But Merck shares Remicade [...]
Continue reading this article »
Share This Article: